Checks CD56 Marker Levels in People With Blood Cancers
Studies how the CD56 marker appears in various blood cancers.
Plain-language title generated from the registry record
Registry title: Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
Key facts
- Where
- Asyut, EgyptSee the site
Where in Egypt
- Assiut UniversityAsyut, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Asmaa Hassan mohamed Abdel Mawjoud
- Trial code
- NCT04546945
- Record updated
- 18 March 2026
- Original description
CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.Read full original descriptionShow less
Resident Doctor at Clinical Pathology Department
CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.
Inclusion: Patients with hematologic malignancies; Newly diagnosed.
Exclusion: Patients with hematologic disorders other than hematologic malignancies.